RESUMEN
The development of a new series of p38α inhibitors resulted in the identification of two clinical candidates, one of which was advanced into a phase 2 clinical study for rheumatoid arthritis. The original lead, an lck inhibitor that also potently inhibited p38α, was a screening hit from our kinase inhibitor library. This manuscript describes the optimization of the lead to p38-selective examples with good pharmacokinetic properties.
Asunto(s)
Descubrimiento de Drogas/métodos , Proteína Quinasa 14 Activada por Mitógenos/antagonistas & inhibidores , Piridonas/farmacología , Piridonas/farmacocinética , Pirimidinas/farmacología , Pirimidinas/farmacocinética , Administración Oral , Artritis Reumatoide/tratamiento farmacológico , Disponibilidad Biológica , Línea Celular , Ensayos Clínicos como Asunto , Humanos , Proteína Quinasa 14 Activada por Mitógenos/química , Modelos Moleculares , Conformación Proteica , Inhibidores de Proteínas Quinasas/administración & dosificación , Inhibidores de Proteínas Quinasas/química , Inhibidores de Proteínas Quinasas/farmacocinética , Inhibidores de Proteínas Quinasas/farmacología , Piridonas/administración & dosificación , Piridonas/química , Pirimidinas/administración & dosificación , Pirimidinas/química , Relación Estructura-Actividad , Especificidad por SustratoRESUMEN
A novel class of highly selective inhibitors of p38 MAP kinase was discovered from high throughput screening. The synthesis and optimization of a series of 5-amino-N-phenyl-1H-pyrazol-4-yl-3-phenylmethanones is described. An X-ray crystal structure of this series bound in the ATP binding pocket of unphosphorylated p38alpha established the presence of a unique hydrogen bond between the exocyclic amine of the inhibitor and threonine 106 which likely contributes to the selectivity for p38. The crystallographic information was used to optimize the potency and physicochemical properties of the series. The incorporation of the 2,3-dihydroxypropoxy moiety on the pyrazole scaffold resulted in a compound with excellent drug-like properties including high oral bioavailability. These efforts identified 63 (RO3201195) as an orally bioavailable and highly selective inhibitor of p38 which was selected for advancement into Phase I clinical trials.